MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2019
Billion doses of treatment supplied to date
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2019
After nearly 10 years of operations, the Medicines Patent Pool went to India to see first-hand how access to quality-assured generic medicines for HIV and hepatitis C has changed people’s life. In the first of our impact series videos, patients, medical experts, governments, among others, explain how MPP’s work has generated impact. From saving lives to increased access, originators, generic manufacturers and committed partners have worked with MPP to deliver the best quality treatments to those who need them most.
Below are stories and testimonies from people in some of the countries benefiting from these agreements, on how being able to access DTG has made a difference to them. Click here to read more.
Kyrgyzstan“Almost everyone now wants dolutegravir, but we are trying to make this transition period gradual ... and people are very much looking forward to receiving TLD, the once-daily pill containing dolutegravir”
South Africa“The improved quality of life experienced by dolutegravir-users, after the side effects of other treatment regimens, has been outstanding […]”
Armenia“We will continue to monitor availability of DTG in Armenia […]. It is very important that we encourage the usage of these drugs as they solve the problem of adherence.”
Malawi“In my community and through my advocacy work, it is clear that dolutegravir is able to change the lives of people living with HIV.”